gtag('config', 'AW-10935689431');

About Us

Iktos was founded in 2016 by Quentin Perron, Nicolas Do Huu, and Yann Gaston-Mathé, with the aim of developing an innovative and user-friendly technology platform for deep learning-based de novo drug design, leveraging a proprietary algorithm developed by Quentin and Nicolas. This proprietary technology enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. Today, Iktos is a leading player in AI-based generative chemistry having delivered value in 50-plus real world research collaborations with some of the most eminent pharma companies globally.

Did you know?

‘Iktos’ stands for ‘God of Dream Catcher’ in the Native American mythology. A lot of terms used at Iktos have Native American origins.

Soon after inception, Iktos started its first collaboration project in 2017. An initial success and first real world validation of the technology was achieved in 2018 in a collaboration with Servier. In 2019, Iktos established its presence in North America by incorporating Iktos Inc. and secured seed funding, as well as non-dilutive finances to grow its AI for de novo drug design technology and software. In the same year, Iktos won its first client for Makya, a SaaS generative AI software platform. In 2020, Iktos released Spaya, Iktos synthesis planning software, and made it available publicly for users to use and evaluate. Over the past few years, Iktos has won various grant competitions and raised equity from a pool of private investors. In 2021, Iktos received a large non-dilutive funding for its robotics platform. In a short span of time, Iktos has successfully delivered multiple projects for global bio-pharma collaborators, thanks to its growing team, comprising of 45 talented individuals spread across France, the UK and the US.


Yann Gaston-Mathe

Co-Founder and CEO

MS Ecole Polytechnique Paris and AgroParisTech. 20+ years experience in pharma R&D, strategic consulting and entrepreneurship in biotech.

Co-founder and CEO, Yann leads the development of Iktos with his knowledge of the pharmaceutical industry and a broad understanding of methods, approaches and tools of data science.

Quentin Perron

Co-Founder and CSO

PhD in organometallic chemistry from University of Geneva.  Medicinal chemist, skilled data scientist.

Co-founder and CSO, Quentin plays a key role in the strategic steering of IKTOS’s R&D and portfolio development and supervision of project delivery for partners and customers.

Nicolas Do Huu

Co-Founder and CTO

PhD in Artificial Intelligence. Several years experience in software development and R&D. Contributed to the emerging data science field by creating distributed computation platform for Big Data processing. 

Co-founder and CTO at Iktos, Nicolas leads the technological developments of the company.

Management Team

Stephane Milot

Chief Financial Officer

Master’s in Accounting-Control-Audit from University Paris Dauphine. Over 20 years of experience as CFO in medical start-ups. Strong experience in capital raising, entrepreneurship and private business financing. Now CFO at Iktos.

Marion Laguette

Associate Director, Strategic Planning and Corporate Development

Engineering degree from Ecole Polytechnique and Master’s in Applied Biosciences & Biotechnology from Imperial College London. In charge of strategic planning & corporate development  at Iktos.

Alessandro Monge

SVP- US Operations

PhD in Theoretical Physics and post-doc research in  protein folding. VP Business Development at Schrodinger for 16 years. Now in charge of developing and managing the Company’s US operations and business development.

Sree Vadlamudi

VP-Head of BD, EU, RoW

PhD in Medicinal Chemistry, MBA from Lancaster Business School. Over 10 years experience in strategic BD positions in bio-pharma industry. Now VP, Head of BD, EU, RoW for Iktos.

Brice Hoffmann

Head of Computational Chemistry

PhD and post-doc in Bioinformatics. Spearheaded the development of Iktos structure-based generative modeling technology and pipeline. Head of Iktos modeling team.

Hamza Tajmouati

Head of AI research and Data Science

Master’s in Applied Mathematics and Computer Science. Key contributor to the development of Iktos generative modeling technology. Lead developer of Iktos retrosynthesis technology.

Abderraouf El Gasser

Head of Platform Development

Master’s in Software Engineering. 15 years experience as CTO, successful experience of software product development. In charge of the software development team.

Cedric Thao

Head of IT Engineering

Master’s in Computer Science. Previous experience as Data scientist and data engineer. Head of the Engineering Group, in charge of Iktos infrastructure and industrialisation of Iktos algorithms.

Christopher Houssemann

Head of Medicinal Chemistry

PhD in chemistry. Over 12 years of experience of medicinal chemistry. Project leader in a med chem project that successfully delivered a drug candidate. Now leads the Med Chem team at Iktos.

Jean Christophe Meillon

Head of Robotics Lab

PhD in organic chemistry. Research Associate at the University of Cambridge. Senior Research Scientist at Idenix Pharmaceuticals. Co-founder and Medicinal Chemistry Director at Oxeltis. 20 years of experience in the pharmaceutical industry. Now, Head of Robotics, Iktos.

Philippe Gendreau

Head of Collaborative Projects

Master’s in Executive Engineering. Research experience in microfluidics. Active in R&D predictive modeling and the development of production-grade tools. In charge of service collaborations at Iktos.

Dara Phonekeo

Office and HR Manager

Degree in Communication from RMIT Melbourne. Over 10 years of experience as an Executive Assistant and Office Manager. Ran business as a fitness coach, certified yoga and Pilates teacher. Responsible for the smooth functioning of the company.

Founded in 2016

Only company to offer generative modeling with synthetic accessibility for successful drug discovery

Customizable technology offering multiple proprietary algorithms

Clients include large/medium pharma, biotech companies and research institutes globally